Payment overview · 2025
General Payments
$1,956.14
135 reported records · 18 companies
Healthcare provider profile · identity verified
Nathan W Turney, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · JONESBORO, AR · NPI 1346207115
Verified facts
What the public records show
CMS Open Payments records show Nathan W Turney, M.D. received $1,956.14 in general payments during 2025 across 135 reported records.
ABBVIE INC. accounted for 17.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Trintellix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 582 claims for Eliquis by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $347.88 | 17.8% | 32 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $334.87 | 17.1% | 28 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $214.95 | 11.0% | 13 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $174.49 | 8.9% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $174.43 | 8.9% | 14 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $147.07 | 7.5% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $142.11 | 7.3% | 12 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $104.66 | 5.3% | 4 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$96.01 | 4.9% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $40.05 | 2.0% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $37.48 | 1.9% | 2 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $29.02 | 1.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $28.05 | 1.4% | 2 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $20.47 | 1.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.74 | 1.0% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.98 | 0.8% | 1 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $15.28 | 0.8% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $13.60 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,956.14 | 135 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $334.87 | 28 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $272.73 | 25 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $255.00 | 15 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $229.19 | 18 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $178.78 | 18 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $139.67 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $107.96 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $105.68 | 10 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $104.66 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $99.07 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $99.07 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $93.68 | 8 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $76.86 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $76.86 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $64.26 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $57.81 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $55.84 | 5 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $48.43 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $48.00 | 4 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $40.74 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $37.48 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $33.31 | 5 | 2025 |
Source payment records
|
|||||
| OSTEOCOOL RF ABLATION SYSTEM Normalized: osteocool rf ablation system |
Device | Medtronic, Inc. | $29.21 | 1 | 2025 |
Source payment records
|
|||||
| GOMEKLI Normalized: gomekli |
Drug | SpringWorks Therapeutics, Inc. | $29.02 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $28.05 | 2 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $26.06 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $20.47 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $19.74 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $15.98 | 1 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $15.28 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $13.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 582 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 85 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 148 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 70 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 103 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
134 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
85 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
148 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
70 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
103 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
582 | 56 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1196 | 214 |
| Lisinopril | Lisinopril | 669 | 115 |
| Levothyroxine Sodium | Levothyroxine Sodium | 668 | 104 |
| Gabapentin | Gabapentin | 653 | 105 |
| Eliquis | Apixaban | 582 | 56 |
| Furosemide | Furosemide | 575 | 108 |
| Amlodipine Besylate | Amlodipine Besylate | 543 | 107 |
| Alprazolam | Alprazolam | 535 | 83 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 534 | 106 |
| Potassium Chloride | Potassium Chloride | 471 | 80 |
| Duloxetine Hcl | Duloxetine Hcl | 445 | 66 |
| Carvedilol | Carvedilol | 415 | 58 |
| Metformin Hcl | Metformin Hcl | 384 | 70 |
| Pantoprazole Sodium | Pantoprazole Sodium | 384 | 99 |
| Tamsulosin Hcl | Tamsulosin Hcl | 384 | 76 |
| Omeprazole | Omeprazole | 371 | 89 |
| Trazodone Hcl | Trazodone Hcl | 340 | 81 |
| Clopidogrel | Clopidogrel Bisulfate | 308 | 53 |
| Sertraline Hcl | Sertraline Hcl | 258 | 46 |
| Donepezil Hcl | Donepezil Hcl | 255 | 43 |
| Meloxicam | Meloxicam | 250 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 244 | 46 |
| Losartan Potassium | Losartan Potassium | 239 | 59 |
| Metoprolol Tartrate | Metoprolol Tartrate | 234 | 48 |
| Tramadol Hcl | Tramadol Hcl | 225 | 58 |
| Mirtazapine | Mirtazapine | 214 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 209 | 47 |
| Allopurinol | Allopurinol | 196 | 36 |
| Simvastatin | Simvastatin | 194 | 28 |
| Memantine Hcl | Memantine Hcl | 190 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 179 | 39 |
| Divalproex Sodium | Divalproex Sodium | 174 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 166 | 31 |
| Bupropion Xl | Bupropion Hcl | 165 | 35 |
| Tizanidine Hcl | Tizanidine Hcl | 163 | 33 |
| Fluoxetine Hcl | Fluoxetine Hcl | 162 | 35 |
| Ropinirole Hcl | Ropinirole Hcl | 162 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 158 | 34 |
| Jardiance | Empagliflozin | 148 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 145 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 145 | 22 |
| Montelukast Sodium | Montelukast Sodium | 143 | 29 |
| Januvia | Sitagliptin Phosphate | 141 | 12 |
| Clonazepam | Clonazepam | 140 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 138 | 29 |
| Buspirone Hcl | Buspirone Hcl | 136 | 30 |
| Myrbetriq | Mirabegron | 134 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 130 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 123 | 22 |
| Levetiracetam | Levetiracetam | 122 | 16 |
| Estradiol | Estradiol | 121 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 120 | 52 |
| Fenofibrate | Fenofibrate | 120 | 24 |
| Aripiprazole | Aripiprazole | 117 | 18 |
| Spironolactone | Spironolactone | 114 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 113 | 25 |
| Celecoxib | Celecoxib | 111 | 26 |
| Diazepam | Diazepam | 110 | 21 |
| Ozempic | Semaglutide | 103 | 19 |
| Atenolol | Atenolol | 102 | 24 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 97 | 18 |
| Amiodarone Hcl | Amiodarone Hcl | 96 | 19 |
| Entresto | Sacubitril/Valsartan | 96 | suppressed |
| Bumetanide | Bumetanide | 94 | 18 |
| Baclofen | Baclofen | 93 | 14 |
| Xarelto | Rivaroxaban | 88 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 87 | 23 |
| Sucralfate | Sucralfate | 87 | 18 |
| Ezetimibe | Ezetimibe | 86 | 14 |
| Farxiga | Dapagliflozin Propanediol | 85 | suppressed |
| Pregabalin | Pregabalin | 85 | 24 |
| Dicyclomine Hcl | Dicyclomine Hcl | 81 | 16 |
| Finasteride | Finasteride | 81 | 13 |
| Glipizide | Glipizide | 78 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 75 | 17 |
| Ondansetron Odt | Ondansetron | 73 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 72 | 17 |
| Famotidine | Famotidine | 71 | 14 |
| Lorazepam | Lorazepam | 70 | 21 |
| Mounjaro | Tirzepatide | 70 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 67 | 12 |
| Albuterol Sulfate | Albuterol Sulfate | 66 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 63 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 63 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 62 | 19 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 61 | 11 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 60 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 59 | 17 |
| Propranolol Hcl | Propranolol Hcl | 58 | 13 |
| Cephalexin | Cephalexin | 57 | 46 |
| Torsemide | Torsemide | 57 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 53 | 15 |
| Alendronate Sodium | Alendronate Sodium | 52 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 52 | 13 |
| Nifedipine Er | Nifedipine | 51 | suppressed |
| Trulicity | Dulaglutide | 51 | suppressed |
| Amoxicillin | Amoxicillin | 50 | 43 |
| Glipizide Er | Glipizide | 50 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 50 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 50 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 49 | 46 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 49 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 49 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 49 | suppressed |
| Novolog | Insulin Aspart | 48 | 14 |
| Prednisone | Prednisone | 48 | 30 |
| Primidone | Primidone | 48 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 48 | 14 |
| Glimepiride | Glimepiride | 47 | 14 |
| Methylprednisolone | Methylprednisolone | 47 | 43 |
| Ramipril | Ramipril | 47 | suppressed |
| Synthroid | Levothyroxine Sodium | 46 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 46 | 14 |
| Azithromycin | Azithromycin | 45 | 38 |
| Doxycycline Hyclate | Doxycycline Hyclate | 45 | 38 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 44 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 43 | 27 |
| Bupropion Hcl Sr | Bupropion Hcl | 42 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 40 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 39 | suppressed |
| Valsartan | Valsartan | 39 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 39 | 11 |
| Methocarbamol | Methocarbamol | 38 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 37 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 37 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 37 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 31 |
| Warfarin Sodium | Warfarin Sodium | 37 | suppressed |
| Lovastatin | Lovastatin | 36 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | 11 |
| Fluconazole | Fluconazole | 35 | 25 |
| Olanzapine | Olanzapine | 35 | suppressed |
| Latanoprost | Latanoprost | 34 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 33 | suppressed |
| Lamotrigine | Lamotrigine | 33 | suppressed |
| Sotalol | Sotalol Hcl | 33 | 11 |
| Procrit | Epoetin Alfa | 32 | suppressed |
| Eszopiclone | Eszopiclone | 31 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 31 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 30 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Naproxen | Naproxen | 29 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 27 |
| Symbicort | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 28 | suppressed |
| Nitroglycerin | Nitroglycerin | 28 | 20 |
| Solifenacin Succinate | Solifenacin Succinate | 28 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Cefdinir | Cefdinir | 26 | 25 |
| Digoxin | Digoxin | 26 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Ibuprofen | Ibuprofen | 26 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 24 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 24 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 24 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 24 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 21 |
| Linzess | Linaclotide | 24 | suppressed |
| Ranolazine Er | Ranolazine | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 23 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 23 | suppressed |
| Fentanyl | Fentanyl | 22 | suppressed |
| Galantamine Er | Galantamine Hbr | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 21 | suppressed |
| Brilinta | Ticagrelor | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Nystatin | Nystatin | 20 | 12 |
| Scopolamine | Scopolamine | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 18 |
| Divalproex Sodium Er | Divalproex Sodium | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Dexamethasone | Dexamethasone | 17 | 15 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 17 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 16 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | 14 |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 15 | 13 |
| Mupirocin | Mupirocin | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Paliperidone Er | Paliperidone | 14 | suppressed |
| Phenytoin | Phenytoin | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 14 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Travoprost | Travoprost | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Insulin Aspart | Insulin Aspart | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Prozac | Fluoxetine Hcl | 12 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 11 | suppressed |
| Pentoxifylline | Pentoxifylline | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,956.14 · 135 records | ABBVIE INC. | AIRSUPRA, Auvelity, BREZTRI, ELIQUIS, EVENITY, FARXIGA, GOMEKLI, INCEPTIV, INTELLIS ADAPTIVESTIM, JARDIANCE, KISUNLA, Kerendia, MOUNJARO, NP Thyroid 60, NURTEC ODT, OSTEOCOOL RF ABLATION SYSTEM, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, TRINTELLIX, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XYOSTED, ZAVZPRET, ZENPEP, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error